Clinical outcome after front-line intensive sequential chemotherapy (ISC) in patients with aggressive non-Hodgkin's lymphoma and high-risk international prognostic index (IPI 3): Final analysis of survival in two consecutive ISC trials

Annals of Oncology

Volumn 12, Issue 4, 2001, Pages 513-517

  Bouabdallah, R ^a   Stoppa, A M ^a   Coso, D ^a   Bardou, V J ^a   Blaise, D ^a   Chabannon, C ^a   Gastaut, J A ^a   Maraninchi, D ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

Aggressive lymphomas; High dose therapy; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISOLONE; VINCRISTINE SULFATE;

ADULT; ARTICLE; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; MALE; NONHODGKIN LYMPHOMA; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0034996851     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011160207382     Document Type: Article

References (15)

1. Harris NL, Jaffe ES, Stein H et al. A Revised European American Classification of lymphoid neoplasms. A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
2. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-6.
3. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-94.
4. Freedman AS, Takvorian T, Neuberg D et al. Aulologous bone marrow transplantation in poor-prognosis intermediate and high-grade B-cell non-Hodgkin's lymphoma in first remission. A pilot study. J Clin Oncol 1993; 11: 931-6.
5. Vitolo U, Cortellazzo S, Liberati AM et al. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. J Clin Oncol 1997; 15: 491-8.
6. Perry AR, Goldstone AH. High-dose therapy for diffuse large-cell lymphoma in first remission. Ann Oncol 1998; 9 (Suppl 1): 9-14.
7. Stoppa AM, Bouabdallah R, Chabannon C et al. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 1722-9.
8. Bouabdallah R, Stoppa AM, Rossi JF et al. Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high-intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin's lymphoma: An oligocentric report on 42 patients. Leukemia 1999; 13: 950-6.
9. Shipp MA, Neuberg D, Janicek M et al. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma. A dose-finding pilot study. J Clin Oncol 1995; 13: 2916-23.
10. Santoro A, Balzarotti M, Tondini C et al. Dose-escalation of CHOP in non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 519-25.
11. Gordon LI, Young M, Weller E et al. A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: Analysis of response, toxicity, and dose intensity. Blood 1999; 94: 3307-14.
12. Nademanee A, Molina A, O'Donnell MR et al. Results of high-dose therapy and autologous hone marrow stem cell transplantation during remission in poor-risk intermediate and high-grade lymphoma. International index high and high-intermediate risk group. Blood 1997; 90: 3844-52.
13. Cortelazzo S, Rossi A, Bellavita P et al. Clinical outcome after autologous transplantation in non-Hodgkin's lymphoma patients with high international prognostic index (IPI). Ann Oncol 1999; 10: 427-32.
14. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol-A Groupe d'Etude des Lymphomes de l'Adulte Study. J Clin Oncol 2000; 16: 3025-30.
15. Shipp MA, Abeloff MD, Antman KH et al. International consensus conference on high-dose therapy with hematopoielic stem-cell transplantation in aggressive non-Hodgkin's lymphoma: Report of the jury. Ann Oncol 1999; 10: 13-9.